Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nanobiotix S.A. - Sponsored ADR (NBTX : NSDQ)
 
 • Company Description   
NANOBIOTIX is a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases. NANOBIOTIX is based in CAMBRIDGE, Mass.

Number of Employees: 97

 
 • Price / Volume Information   
Yesterday's Closing Price: $41.01 Daily Weekly Monthly
20 Day Moving Average: 101,110 shares
Shares Outstanding: 48.52 (millions)
Market Capitalization: $1,989.72 (millions)
Beta: 0.70
52 Week High: $57.14
52 Week Low: $3.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 21.66% 15.71%
12 Week 49.07% 37.81%
Year To Date 77.38% 59.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
60 RUE DE WATTIGNIES
-
PARIS,I0 75012
FRA
ph: 33-1-40-26-04-70
fax: -
None http://www.nanobiotix.com
 
 • General Corporate Information   
Officers
Laurent Levy - Chairman of the Executive Board and Co-founder
Anne-Marie Graffin - Vice Chairwoman
Bart Van Rhijn - Chief Financial and Business Officer
Alain Herrera - Member
Enno Spillner - Member

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 63009J107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 48.52
Most Recent Split Date: (:1)
Beta: 0.70
Market Capitalization: $1,989.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 219.69
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -
12/31/25 - -
09/30/25 - -
ROA
03/31/26 - -
12/31/25 - -
09/30/25 - -
Current Ratio
03/31/26 - -
12/31/25 - 1.09
09/30/25 - -
Quick Ratio
03/31/26 - -
12/31/25 - 1.09
09/30/25 - -
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -73.51
09/30/25 - -
Book Value
03/31/26 - -
12/31/25 - -1.97
09/30/25 - -
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Capital
03/31/26 - -
12/31/25 - -
09/30/25 - -
 

Powered by Zacks Investment Research ©